Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1987-4-29
|
pubmed:abstractText |
CR 1409, a glutaramic acid derivative with competitive cholecystokinin-antagonistic activity, was administered IP and evaluated in comparison with proglumide (the model CCK-receptor antagonist), gabexate (protease inhibitor) and PGE2 (cytoprotective) on two different models of experimental pancreatitis. Acute pancreatitis was induced in mice by six IP injections of 50 micrograms/kg caerulein at hourly intervals. The drugs were administered 30 minutes before each caerulein administration. Blood samples and pancreata were collected 3 hours after the last caerulein injection. In the second experiment, pancreatitis was induced in rats by injecting 0.3 ml 6% sodium taurocholate interstitially into the pancreas. The drugs were administered twice, 30 minutes before and 3 hours after taurocholate. The animals were killed 6 hours after laparotomy and blood samples and pancreata were collected. CR 1409 exhibited on both pancreatitis models a protective effect in a dose range of 0.3-10 mg/kg. Proglumide exhibited a protective activity at higher doses (200-400 mg/kg). Gabexate and PGE2 were effective only in pancreatitis induced by taurocholate in a dose range of 30-60 mg/kg and 60-130 micrograms/kg respectively. These results, showing a high protective effect of CR 1409 on different models of acute pancreatitis, suggest an important role of CCK in the pathogenesis of pancreatitis.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Caerulein,
http://linkedlifedata.com/resource/pubmed/chemical/Cholecystokinin,
http://linkedlifedata.com/resource/pubmed/chemical/Dinoprostone,
http://linkedlifedata.com/resource/pubmed/chemical/Gabexate,
http://linkedlifedata.com/resource/pubmed/chemical/Glutamine,
http://linkedlifedata.com/resource/pubmed/chemical/Guanidines,
http://linkedlifedata.com/resource/pubmed/chemical/Proglumide,
http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandins E,
http://linkedlifedata.com/resource/pubmed/chemical/Taurocholic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/lorglumide
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0196-9781
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
7
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1159-64
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3104890-Acute Disease,
pubmed-meshheading:3104890-Animals,
pubmed-meshheading:3104890-Caerulein,
pubmed-meshheading:3104890-Cholecystokinin,
pubmed-meshheading:3104890-Dinoprostone,
pubmed-meshheading:3104890-Disease Models, Animal,
pubmed-meshheading:3104890-Female,
pubmed-meshheading:3104890-Gabexate,
pubmed-meshheading:3104890-Glutamine,
pubmed-meshheading:3104890-Guanidines,
pubmed-meshheading:3104890-Male,
pubmed-meshheading:3104890-Mice,
pubmed-meshheading:3104890-Pancreatitis,
pubmed-meshheading:3104890-Proglumide,
pubmed-meshheading:3104890-Prostaglandins E,
pubmed-meshheading:3104890-Rats,
pubmed-meshheading:3104890-Rats, Inbred Strains,
pubmed-meshheading:3104890-Taurocholic Acid
|
pubmed:articleTitle |
Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and mice.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|